Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
ISRN Pharmacology
|
April 24, 2012
Pharmacodynamic modelling of biomarker data in oncology
Robert C Jackson
The AAPS Journal
|
March 24, 2016
Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib
Robert C Jackson, Tomas Radivoyevitch
Cancer Chemotherapy and Pharmacology
|
August 10, 2014
A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia
Robert C Jackson, Tomas Radivoyevitch
Biodiscovery
|
April 26, 2014
Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of Seliciclib
Robert C Jackson, Tomas Radivoyevitch
Peerj
|
May 22, 2020
The spindle assembly checkpoint and speciation
Robert C Jackson, Hitesh B Mistry
Journal of Pharmacokinetics and Pharmacodynamics
|
August 10, 2010
An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor
Hiroko Kamei, Robert C Jackson, Daniella Zheleva, et al.
BMC Cancer
|
April 28, 2006
On systems and control approaches to therapeutic gain
Tomas Radivoyevitch, Kenneth A Loparo, Robert C Jackson, et al.
Expert Opinion on Drug Discovery
|
March 14, 2013
Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases
Robert C Jackson, Anna L Barnett, Steven J McClue, et al.
Frontiers in Bioscience (Landmark Edition)
|
December 29, 2009
A pharmacodynamic model of Aurora kinase inhibitors in the spindle assembly checkpoint
Hitesh B Mistry, David E MacCallum, Robert C Jackson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 19, 2008
Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase
Hitesh B Mistry, David E MacCallum, Robert C Jackson, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
ISRN Pharmacology
|
April 24, 2012
Pharmacodynamic modelling of biomarker data in oncology
Robert C Jackson
The AAPS Journal
|
March 24, 2016
Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib
Robert C Jackson, Tomas Radivoyevitch
Cancer Chemotherapy and Pharmacology
|
August 10, 2014
A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia
Robert C Jackson, Tomas Radivoyevitch
Biodiscovery
|
April 26, 2014
Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of Seliciclib
Robert C Jackson, Tomas Radivoyevitch
Peerj
|
May 22, 2020
The spindle assembly checkpoint and speciation
Robert C Jackson, Hitesh B Mistry
Journal of Pharmacokinetics and Pharmacodynamics
|
August 10, 2010
An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor
Hiroko Kamei, Robert C Jackson, Daniella Zheleva, et al.
BMC Cancer
|
April 28, 2006
On systems and control approaches to therapeutic gain
Tomas Radivoyevitch, Kenneth A Loparo, Robert C Jackson, et al.
Expert Opinion on Drug Discovery
|
March 14, 2013
Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases
Robert C Jackson, Anna L Barnett, Steven J McClue, et al.
Frontiers in Bioscience (Landmark Edition)
|
December 29, 2009
A pharmacodynamic model of Aurora kinase inhibitors in the spindle assembly checkpoint
Hitesh B Mistry, David E MacCallum, Robert C Jackson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 19, 2008
Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase
Hitesh B Mistry, David E MacCallum, Robert C Jackson, et al.
Page
of 2